236 related articles for article (PubMed ID: 34420429)
1. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials.
Bourien H; Lamarca A; McNamara MG; Hubner RA; Valle JW; Edeline J
Expert Opin Investig Drugs; 2021 Sep; 30(9):975-983. PubMed ID: 34420429
[No Abstract] [Full Text] [Related]
2. Cholangiocarcinoma: shedding light on the most promising drugs in clinical development.
Rahnemai-Azar AA; Pawlik TM
Expert Opin Investig Drugs; 2021 Apr; 30(4):419-427. PubMed ID: 33645382
[No Abstract] [Full Text] [Related]
3. Therapeutic challenges at the preclinical level for targeted drug development for
Loilome W; Dokduang H; Suksawat M; Padthaisong S
Expert Opin Investig Drugs; 2021 Sep; 30(9):985-1006. PubMed ID: 34292795
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
6. Cholangiocarcinoma: novel therapeutic targets.
Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
[No Abstract] [Full Text] [Related]
7. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.
Cadamuro M; Lasagni A; Lamarca A; Fouassier L; Guido M; Sarcognato S; Gringeri E; Cillo U; Strazzabosco M; Marin JJ; Banales JM; Fabris L
Expert Opin Investig Drugs; 2021 Apr; 30(4):377-388. PubMed ID: 33622120
[No Abstract] [Full Text] [Related]
8. Emerging pathways for precision medicine in management of cholangiocarcinoma.
Rahnemai-Azar AA; Abbasi A; Acher AW; Weber SM; Pawlik TM
Surg Oncol; 2020 Dec; 35():47-55. PubMed ID: 32827952
[TBL] [Abstract][Full Text] [Related]
9. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
[TBL] [Abstract][Full Text] [Related]
10. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of identifying genetic abnormalities that can be targeted in cholangiocarcinomas.
Testa U; Pelosi E; Castelli G
Expert Rev Anticancer Ther; 2023 Feb; 23(2):147-162. PubMed ID: 36654529
[TBL] [Abstract][Full Text] [Related]
12. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
13. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials.
Uson Junior PLS; Bearss J; Babiker HM; Borad MJ
Expert Opin Investig Drugs; 2023 Jan; 32(1):69-75. PubMed ID: 36714945
[TBL] [Abstract][Full Text] [Related]
14. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.
Baiocchi L; Sato K; Ekser B; Kennedy L; Francis H; Ceci L; Lenci I; Alvaro D; Franchitto A; Onori P; Gaudio E; Wu C; Chakraborty S; Glaser S; Alpini G
Expert Opin Investig Drugs; 2021 Apr; 30(4):365-375. PubMed ID: 33226854
[No Abstract] [Full Text] [Related]
15. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH; Tan E; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):333-341. PubMed ID: 33378249
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Wang J; Ilyas S
Expert Opin Investig Drugs; 2021 Apr; 30(4):429-438. PubMed ID: 33322977
[No Abstract] [Full Text] [Related]
17. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
18. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
19. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]